Neuberger Berman High Yield Strategies Fund (NYSEAMERICAN:NHS) Shares Pass Below 200-Day Moving Average - Here's Why

Key Points

• Shares of Neuberger Berman High Yield Strategies Fund (NHS) fell below its 200‑day moving average
• The fund declared a monthly dividend of $0.0905 (ex‑dividend and record date April 7; payable April 30), implying an annualized yield of 16.6%.
• Institutional investors boosted positions in Q4—most notably Guggenheim Capital (+38% to 567,943 shares)—suggesting rising institutional interest despite the recent technical weakness.

Shares of Neuberger Berman High Yield Strategies Fund (NYSEAMERICAN:NHS - Get Free Report) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $7.26 and traded as low as $6.52. Neuberger Berman High Yield Strategies Fund shares last traded at $6.54, with a volume of 115,403 shares traded.

Neuberger Berman High Yield Strategies Fund Trading Up 0.3%

The company's 50 day moving average price is $7.07 and its 200-day moving average price is $7.26.

Neuberger Berman High Yield Strategies Fund Announces Dividend

The company also recently disclosed a monthly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, April 7th will be issued a $0.0905 dividend. The ex-dividend date is Tuesday, April 7th. This represents a c) dividend on an annualized basis and a yield of 16.6%.

Institutional Investors Weigh In On Neuberger Berman High Yield Strategies Fund

A number of institutional investors have recently modified their holdings of NHS. Mercer Global Advisors Inc. ADV lifted its stake in Neuberger Berman High Yield Strategies Fund by 24.4% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 13,244 shares of the investment management company's stock valued at $99,000 after purchasing an additional 2,597 shares during the last quarter. Guggenheim Capital LLC boosted its holdings in shares of Neuberger Berman High Yield Strategies Fund by 38.0% during the 4th quarter. Guggenheim Capital LLC now owns 567,943 shares of the investment management company's stock worth $4,225,000 after buying an additional 156,386 shares during the period. Cetera Investment Advisers grew its position in Neuberger Berman High Yield Strategies Fund by 232.1% in the 4th quarter. Cetera Investment Advisers now owns 36,883 shares of the investment management company's stock worth $274,000 after purchasing an additional 25,777 shares during the last quarter. Osaic Holdings Inc. lifted its holdings in shares of Neuberger Berman High Yield Strategies Fund by 86.2% during the 4th quarter. Osaic Holdings Inc. now owns 74,294 shares of the investment management company's stock worth $553,000 after acquiring an additional 34,387 shares during the period. Finally, Kestra Advisory Services LLC lifted its holdings in shares of Neuberger Berman High Yield Strategies Fund by 18.0% during the 4th quarter. Kestra Advisory Services LLC now owns 18,728 shares of the investment management company's stock worth $139,000 after acquiring an additional 2,857 shares during the period.

Neuberger Berman High Yield Strategies Fund Company Profile

The Neuberger Berman High Yield Strategies Fund (NYSE American: NHS) is a closed-end, fixed-income management investment company focused on delivering high current income with the potential for capital appreciation. The fund primarily invests in below-investment-grade corporate debt—often referred to as high-yield bonds—issued by U.S. and select non-U.S. issuers. Through a diversified portfolio of high-yield instruments, NHS aims to provide enhanced yield relative to investment-grade alternatives.

Under its investment policy, NHS allocates the majority of its assets to corporate securities spanning sectors such as communications, energy, consumer goods, and industrials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.